112 related articles for article (PubMed ID: 34717193)
1. Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer.
Liu L; Cai L; Du X; Zhao J; Zhao Y; Zou C; Yu S; Zhang C; Ye P; Su X; Yan X; Li W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108302. PubMed ID: 34717193
[TBL] [Abstract][Full Text] [Related]
2. Radiation Augments the Local Anti-Tumor Effect of
Pieper AA; Zangl LM; Speigelman DV; Feils AS; Hoefges A; Jagodinsky JC; Felder MA; Tsarovsky NW; Arthur IS; Brown RJ; Birstler J; Le T; Carlson PM; Bates AM; Hank JA; Rakhmilevich AL; Erbe AK; Sondel PM; Patel RB; Morris ZS
Front Immunol; 2021; 12():763888. PubMed ID: 34868010
[TBL] [Abstract][Full Text] [Related]
3. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
4. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
5. Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.
Pieper AA; Spiegelman DV; Felder MAR; Feils AS; Tsarovsky NW; Zaborek J; Morris ZS; Erbe AK; Rakhmilevich AL; Sondel PM
Cancer Immunol Immunother; 2023 Jul; 72(7):2459-2471. PubMed ID: 37016127
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
7. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
[TBL] [Abstract][Full Text] [Related]
8. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
[TBL] [Abstract][Full Text] [Related]
9. Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model.
Alvim RG; Georgala P; Nogueira L; Somma AJ; Nagar K; Thomas J; Alvim L; Riegel A; Hughes C; Chen J; Reis AB; Lebdai S; Scherz A; Zanganeh S; Gardner R; Kim K; Coleman JA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205347
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
11.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
12. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
14. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
15. The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma.
Zhou Z; Lin L; An Y; Zhan M; Chen Y; Cai M; Zhu X; Lu L; Zhu K
J Hepatocell Carcinoma; 2021; 8():529-543. PubMed ID: 34136421
[TBL] [Abstract][Full Text] [Related]
16. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer.
Yokouchi H; Yamazaki K; Chamoto K; Kikuchi E; Shinagawa N; Oizumi S; Hommura F; Nishimura T; Nishimura M
Cancer Sci; 2008 Feb; 99(2):361-7. PubMed ID: 18201271
[TBL] [Abstract][Full Text] [Related]
17. An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Wang R; Gao C; Raymond M; Dito G; Kabbabe D; Shao X; Hilt E; Sun Y; Pak I; Gutierrez M; Melero I; Spreafico A; Carvajal RD; Ong M; Olszanski AJ; Milburn C; Thudium K; Yang Z; Feng Y; Fracasso PM; Korman AJ; Aanur P; Huang SA; Quigley M
Clin Cancer Res; 2019 Nov; 25(22):6709-6720. PubMed ID: 31573956
[TBL] [Abstract][Full Text] [Related]
18. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
19. Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination.
Chu Y; Li R; Qian L; Liu F; Xu R; Meng F; Ke Y; Shao J; Yu L; Liu Q; Liu B
Cancer Sci; 2021 Nov; 112(11):4490-4500. PubMed ID: 34537997
[TBL] [Abstract][Full Text] [Related]
20. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
